Ziihera

Ziihera (zanidatamab) is a targeted therapy for HER2-positive cancers, designed to bind and block HER2 receptors. Administered via infusion, it is prescribed for select solid tumors. This overview covers general uses and handling notes. Seek medical guidance for personalized treatment plans.

Zanidatamab is used to treat HER2-positive cancers, including metastatic breast cancer and gastric cancer. It targets HER2 receptors to slow tumor growth and is often combined with other therapies. Patients should discuss eligibility with an oncologist to confirm suitability for this treatment.

Zanidatamab may cause mild to moderate infusion-related reactions, such as fever or chills. Some patients report fatigue or nausea during treatment. These effects are typically temporary and monitored by healthcare providers during administration.

Zanidatamab requires administration under medical supervision due to potential infusion reactions. Patients should disclose all medications and health conditions to their provider. Pregnant or breastfeeding individuals should discuss risks with their doctor before starting treatment.

Zanidatamab may interact with other HER2-targeted therapies or immunosuppressants. Avoid live vaccines during treatment unless approved by a healthcare professional. Inform your provider about all prescription, over-the-counter, and herbal products in use.